OnCusp Therapeutics announced today the clearance of its Investigational New Drug (IND) Application for CUSP06 by the U.S. Food and Drug Administration (FDA).
RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations Read More »
Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology.
Cybin Inc. today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985, to a deuterated psilocybin analog in the Company’s CYB003 investigational drug program.
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
Cardinal Health reported fourth quarter fiscal year 2023 revenues of $53.5 billion, an increase of 13% from the fourth quarter of last year.
The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company’s shareholders.
Bulletin from Swedish Orphan Biovitrum (Sobi)’s Extraordinary General Meeting (EGM) Read More »
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.
USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc. Read More »
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2023.
SINOVAC Reports Unaudited First Half of 2023 Financial Results Read More »
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, reported its unaudited financial results for the three and six months ended June 30, 2023.
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights Read More »
